PHIO — Phio Pharmaceuticals Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1533040 ·
Last close
$0.72
Market Cap
$8.57M
52W High
$1.88
52W Low
$0.70
ADV30
69,655
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,268,000 | -4,160,000 | 11,317,000 | 10,609,000 | 2,697,000 |
| Jun 2026 | 0 | — | -4,268,000 | -4,138,000 | 14,307,000 | 12,996,000 | 1,705,000 |
| Mar 2026 | 0 | — | -4,167,000 | -4,003,000 | 17,412,000 | 17,031,000 | 950,000 |
| Dec 2025 | 0 | — | -2,534,000 | -2,371,000 | 21,487,000 | 21,031,000 | 1,340,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,202,000
Investing CF
$-4,000
Financing CF
$14,427,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-163,195,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,474,000
Pretax Income TTM
$-12,904,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,220,000 | -8,698,000 | 21,487,000 | 1,340,000 | 20,147,000 | -7,979,000 |
| Dec 2024 | 0 | -7,387,000 | -7,150,000 | 5,738,000 | 1,015,000 | 4,723,000 | -7,112,000 |
| Dec 2023 | 0 | -10,698,000 | -10,826,000 | 9,364,000 | 1,634,000 | 7,730,000 | -10,749,000 |
| Dec 2022 | 0 | -11,462,000 | -11,480,000 | 12,814,000 | 1,976,000 | 10,838,000 | -12,129,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-12,904,000
OpCashFlow TTM
—
Assets (Latest)
$14,307,000
Forward EPS
$-0.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DARE | Dare Bioscience, Inc. | $8.44M | $0.43 | — |
| CALC | CalciMedica, Inc. | $8.41M | $1.22 | — |
| LEXX | Lexaria Bioscience Corp. | $8.81M | $4.18 | — |
| VTGN | Vistagen Therapeutics, Inc. | $8.34M | $0.19 | — |
| BFRI | Biofrontera Inc. | $8.81M | $0.59 | — |
News headlines (Yahoo Finance, 1h cache)
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2026-11-12 12:00 · Yahoo
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
2026-11-09 12:00 · Yahoo
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
2026-11-06 17:21 · Yahoo
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
2026-11-06 14:05 · Yahoo
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
2026-10-19 13:53 · Yahoo
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
2026-10-13 11:00 · Yahoo
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
2026-10-06 11:00 · Yahoo
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
2026-10-05 11:00 · Yahoo
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
2026-09-23 11:00 · Yahoo
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
2026-09-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.